Cisplatin Resistance Associated with PARP Hyperactivation

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Robin Angelique) > Cisplatin Resistanc...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		03216naa a2200577 4500
001		oai:DiVA.org:umu-70139
003		SwePub
008		130506s2013 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-701392 URI
024	7	a https://doi.org/10.1158/0008-5472.CAN-12-30002 DOI
040		a (SwePub)umu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Michels, Judith4 aut
245	1 0	a Cisplatin Resistance Associated with PARP Hyperactivation
264	1	a Philadelphia :b American Association for Cancer Research,c 2013
338		a print2 rdacarrier
520		a Non-small cell lung carcinoma patients are frequently treated with cisplatin (CDDP), most often yielding temporary clinical responses. Here, we show that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin. Cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PAR(high)) responded to pharmacologic PARP inhibitors as well as to PARP1-targeting siRNAs by initiating a DNA damage response that translated into cell death following the activation of the intrinsic pathway of apoptosis. Moreover, PARP1-overexpressing tumor cells and xenografts displayed elevated levels of PAR, which predicted the response to PARP inhibitors in vitro and in vivo more accurately than PARP1 expression itself. Thus, a majority of CDDP-resistant cancer cells appear to develop a dependency to PARP1, becoming susceptible to PARP inhibitor-induced apoptosis. Cancer Res; 73(7); 2271-80.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700	1	a Vitale, Ilio4 aut
700	1	a Galluzzi, Lorenzo4 aut
700	1	a Adam, Julien4 aut
700	1	a Olaussen, Ken Andre4 aut
700	1	a Kepp, Oliver4 aut
700	1	a Senovilla, Laura4 aut
700	1	a Talhaoui, Ibtissam4 aut
700	1	a Guegan, Justine4 aut
700	1	a Enot, David Pierre4 aut
700	1	a Talbot, Monique4 aut
700	1	a Robin, Angelique4 aut
700	1	a Girard, Philippe4 aut
700	1	a Orear, Cedric4 aut
700	1	a Lissa, Delphine4 aut
700	1	a Sukkurwala, Abdul Qader4 aut
700	1	a Garcia, Pauline4 aut
700	1	a Behnam Motlagh, Parvizu Umeå universitet,Klinisk kemi4 aut0 (Swepub:umu)pabe0001
700	1	a Kohno, Kimitoshi4 aut
700	1	a Wu, Gen Sheng4 aut
700	1	a Brenner, Catherine4 aut
700	1	a Dessen, Philippe4 aut
700	1	a Saparbaev, Murat4 aut
700	1	a Soria, Jean-Charles4 aut
700	1	a Castedo, Maria4 aut
700	1	a Kroemer, Guido4 aut
710	2	a Umeå universitetb Klinisk kemi4 org
773	0	t Cancer Researchd Philadelphia : American Association for Cancer Researchg 73:7, s. 2271-2280q 73:7<2271-2280x 0008-5472x 1538-7445
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-70139
856	4 8	u https://doi.org/10.1158/0008-5472.CAN-12-3000

Hitta via bibliotek

Cancer Research (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Cancer Research

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se